


Supplementary Fig. S1




- |                                |                                 |                 |                         |                           |                 |
|--------------------------------|---------------------------------|-----------------|-------------------------|---------------------------|-----------------|
| ● Used for paired correlations | ● RNA-seq,WES                   | ● Olink,WES     | ● Olink,Urine ctDNA     | ● RNA-seq,Urine ctDNA,WES | ■ BCG treatment |
| ● Olink,RNA-seq,WES            | ● Urine ctDNA                   | ● WES           | ● RNA-seq               |                           |                 |
| ● Olink                        | ● Olink,RNA-seq,Urine ctDNA,WES | ● Olink,RNA-seq | ● Olink,Urine ctDNA,WES |                           |                 |
- #Analyses for sample
- |     |     |     |     |
|-----|-----|-----|-----|
| ■ 1 | ● 2 | ▲ 3 | ◆ 4 |
|-----|-----|-----|-----|

## Supplementary Fig. S1


Detailed overview of patients disease courses and analyzed samples. Lines represent patient's disease courses from time of first analyzed tumor or urine sample to end of FU centered around the first induction treatment of BCG with at least five instillations. Colors indicate performed analyses. Shapes indicate the number of analyses per clinical timepoint. Left: full FU. Right: Two years pre and post-BCG illustrated.

# Supplementary Fig. S2


**A**




**B**




**C**




**D**



**E**










**F**



## Supplementary Fig. S2

Study and sample overview and RNAseq based analyses. A) Overview of study with disease course including BCG treatment of at least five instillations and sample types at different time points. Dashed lines indicate samples analyzed from a limited number of patients. Design of custom panel for deep targeted sequencing is outlined. Created with BioRender.com (publication license obtained). B) Venn diagram showing overlapping samples between analysis methods. C) Association between UROMOL2021 tumor subtype and time from BCG treatment for all post-BCG samples sequenced for the project (Wilcoxon Rank Sum test). D) CD8 adjusted exhaustion status in BCG-responsive and BCG-failure patients in pre- and post-BCG tumors, respectively (Fisher's Exact test). E) Correlation between CD8 T-cell score and exhaustion score. Green = lower exhaustion (residuals  $\leq 1.04$ ). Purple = excessive exhaustion (residuals  $> 1.04$ ). Pearson correlation was used to determine the correlation coefficient  $R$  and  $p$ -value. F) Excessive exhaustion status in BCG-responsive and BCG-failure patients in pre- and post-BCG tumors, respectively (Fisher's Exact test).

# Supplementary Fig. S3










BCG-responsive BCG-failure

### Supplementary Fig. S3

Correlations between tumor WES characteristics and BCG-response. A) The number of single nucleotide variants (SNVs) in pre-BCG tumor samples correlated to response to BCG. B) The number of INDELs in pre-BCG tumor samples correlated to response to BCG. C) The number of APOBEC-related mutations (SBS2+SBS13) in pre-BCG tumor samples correlated to response to BCG. D) The number of SBS4-related mutations in pre-BCG tumor samples correlated to response to BCG. E) The number of SBS1-related mutations in pre-BCG tumor samples correlated to response to BCG. F) The number of SBS5-related mutations in pre-BCG tumor samples correlated to response to BCG. G) The number of SBS25-related mutations in pre-BCG tumor samples correlated to response to BCG. Green = BCG-responsive patients. Orange = BCG-failure patients. The Wilcoxon Rank Sum test was used for statistical comparisons.

# Supplementary Fig. S4





Exhaustion status post-BCG ■ Higher exhaustion ■ Lower exhaustion

## Supplementary Fig. S4

Correlations between post-BCG tumor exhaustion status and pre-BCG tumor WES characteristics. A) The number of single nucleotide variants (SNVs) in pre-BCG tumor samples correlated to post-BCG exhaustion status. B) The number of INDELS in pre-BCG tumor samples correlated to post-BCG exhaustion status. C) The number of APOBEC-related mutations (SBS2+SBS13) in pre-BCG tumor samples correlated to post-BCG exhaustion status. D) The number of SBS4-related mutations in pre-BCG tumor samples correlated to post-BCG exhaustion status. E) The number of SBS1-related mutations in pre-BCG tumor samples correlated to post-BCG exhaustion status. F) The number of SBS5-related mutations in pre-BCG tumor samples correlated to post-BCG exhaustion status. G) The number of SBS25-related mutations in pre-BCG tumor samples correlated to post-BCG exhaustion status. Pink = Higher post-BCG exhaustion. Turquoise = Lower post-BCG exhaustion. The Wilcoxon Rank Sum test was used for statistical comparisons.



# Supplementary Fig. S5



## Supplementary Fig. S5

Overview of identified mutational signatures. A) Detailed mutational profiles for the six mutational signatures identified by de novo extraction using the R package MutationalPatterns. Extracted signatures were named according to COSMIC signatures with the highest resemblance, as estimated using cosine similarity and resulting in the following values: SBS1 = 0.91, SBS2, 0.92, SBS4 = 0.89, SBS5 = 0.75, SBS13 = 0.76, SBS25 = 0.64. B) Relative contribution of the identified mutational signatures. Sample clustering was performed based on euclidean distances.

# Supplementary Table S1: Olink proteins and results

Overview of analyzed proteins using the Olink proteomics platform and associated biological processes. P-values and Benjamini-Hochberg adjusted P-values from paired t-tests for comparisons between pre-BCG and post-BCG samples for all patients, BCG-responsive patients, and patients with BCG-failure are shown. Green color indicates p-values < 0.05 and blue color indicates q-values < 0.1.

Assay	OlinkID	UniProt	Olink Information	Biological process	All Patients		BCG-responsive		BCG-failure		Test Method
					P-value	Adjusted p-value	P-value	Adjusted p-value	P-value	Adjusted p-value	
ADA	O1D00775	P00813	Metabolism	2,47E-02	9,91E-02	4,12E-02	3,70E-01	1,83E-01	3,11E-01	Paired t-test	
ADGRG1	O1D00754	Q9Y653	Vascular and tissue remodeling	4,50E-02	1,22E-01	8,40E-01	9,94E-01	2,38E-02	1,37E-01	Paired t-test	
ANGPT1	O1D00760	Q15389	Vascular and tissue remodeling	9,39E-01	9,71E-01	6,89E-01	9,74E-01	7,24E-01	7,66E-01	Paired t-test	
ANGPT2	O1D00822	Q15123	Vascular and tissue remodeling	9,99E-01	9,99E-01	1,17E-01	5,68E-01	4,72E-01	5,37E-01	Paired t-test	
ARG1	O1D00815	P05089	Suppresses tumor immunity	8,70E-02	1,96E-01	7,42E-01	9,76E-01	8,75E-02	2,24E-01	Paired t-test	
CAIX	O1D00773	Q15790	Metabolism; Vascular and tissue remodeling	2,37E-01	3,63E-01	9,32E-01	9,94E-01	1,02E-01	2,34E-01	Paired t-test	
CASP-8	O1D00827	Q14790	Apoptosis/cell killing	5,17E-01	5,81E-01	7,78E-01	9,76E-01	3,83E-01	4,90E-01	Paired t-test	
CCL17	O1D00821	Q92583	Chemotaxis; Suppresses tumor immunity	4,45E-01	5,25E-01	5,12E-01	9,01E-01	1,66E-01	3,02E-01	Paired t-test	
CCL19	O1D00794	Q99731	Chemotaxis; Suppresses tumor immunity	6,66E-04	1,14E-02	4,27E-02	3,70E-01	7,09E-03	7,44E-02	Paired t-test	
CCL20	O1D00837	P78556	Chemotaxis; Suppresses tumor immunity	3,75E-02	1,11E-01	3,40E-02	3,70E-01	1,55E-01	2,90E-01	Paired t-test	
CCL23	O1D00811	P55773	Chemotaxis; Vascular and tissue remodeling	1,11E-04	2,55E-03	6,67E-03	1,16E-01	5,56E-03	7,31E-02	Paired t-test	
CCL3	O1D00813	P10147	Chemotaxis	2,22E-01	3,53E-01	3,37E-01	7,53E-01	3,48E-01	4,78E-01	Paired t-test	
CCL4	O1D00796	P13236	Chemotaxis	2,66E-02	9,91E-02	5,55E-02	4,26E-01	1,16E-01	2,38E-01	Paired t-test	
CD244	O1D00758	Q98ZWB	Promotes tumor immunity; Promotes tumor immunity	2,84E-01	4,08E-01	8,71E-01	9,94E-01	9,24E-02	1,42E-01	Paired t-test	
CD27	O1D00800	P26842	Promotes tumor immunity	2,89E-02	9,91E-02	3,12E-01	7,53E-01	5,02E-02	1,75E-01	Paired t-test	
CD28	O1D00793	P10747	Promotes tumor immunity	3,30E-01	4,40E-01	7,27E-01	9,76E-01	3,41E-01	4,75E-01	Paired t-test	
CD4	O1D00776	P01730	Promotes tumor immunity; Suppresses tumor immunity	6,77E-02	1,67E-01	5,19E-01	9,01E-01	5,85E-02	1,75E-01	Paired t-test	
CD40	O1D00781	P25942	Promotes tumor immunity	9,46E-03	6,69E-02	2,55E-01	6,90E-01	1,64E-02	1,00E-01	Paired t-test	
CD40-L	O1D00756	P29965	Apoptosis/cell killing; Promotes tumor immunity	8,03E-01	8,49E-01	6,52E-01	9,76E-01	9,35E-01	9,45E-01	Paired t-test	
CD5	O1D00812	P06127	Promotes tumor immunity; Suppresses tumor immunity	1,96E-03	1,81E-02	1,50E-01	5,87E-01	4,57E-03	7,31E-02	Paired t-test	
CD70	O1D00808	P32970	Promotes tumor immunity	7,48E-04	1,14E-02	3,24E-01	7,53E-01	6,56E-04	1,51E-01	Paired t-test	
CSB3	O1D00841	Q01151	Promotes tumor immunity	2,96E-03	2,47E-02	2,13E-01	6,56E-01	5,46E-03	7,31E-02	Paired t-test	
CSB8	O1D00772	P01732	Promotes tumor immunity	1,60E-02	8,20E-02	1,53E-01	5,87E-01	5,55E-02	1,75E-01	Paired t-test	
CRAM	O1D00756	O95727	Promotes tumor immunity	1,05E-01	2,25E-01	6,00E-01	9,76E-01	1,12E-02	8,33E-02	Paired t-test	
CSF-1	O1D00843	P09603	Suppresses tumor immunity	1,66E-01	3,03E-01	8,25E-01	9,94E-01	1,06E-01	2,38E-01	Paired t-test	
CXCL11	O1D00806	P78423	Chemotaxis; Promotes tumor immunity	2,07E-02	9,52E-02	8,47E-01	9,94E-01	8,02E-03	7,44E-02	Paired t-test	
CXCL1	O1D00786	P09341	Chemotaxis; Suppresses tumor immunity; Vascular and tissue remodeling	4,40E-02	1,22E-01	4,53E-01	8,34E-01	6,28E-02	1,75E-01	Paired t-test	
CXCL10	O1D00807	P03793	Chemotaxis; Promotes tumor immunity; Vascular and tissue remodeling	9,12E-09	9,98E-08	6,87E-05	2,31E-03	1,23E-05	3,78E-04	Paired t-test	
CXCL11	O1D00767	Q14625	Chemotaxis; Promotes tumor immunity; Suppresses tumor immunity; Vascular and tissue remodeling	6,50E-11	3,01E-09	7,25E-06	3,33E-04	1,58E-06	1,45E-04	Paired t-test	
CXCL12	O1D00824	P48061	Chemotaxis; Suppresses tumor immunity; Vascular and tissue remodeling	7,49E-01	8,01E-01	4,26E-01	8,16E-01	7,77E-01	8,12E-01	Paired t-test	
CXCL13	O1D00830	Q43927	Chemotaxis; Promotes tumor immunity; Suppresses tumor immunity	1,10E-02	7,24E-02	2,14E-01	6,56E-01	2,63E-02	1,42E-01	Paired t-test	
CXCL5	O1D00801	P42830	Chemotaxis; Suppresses tumor immunity; Vascular and tissue remodeling	3,74E-01	4,71E-01	7,18E-01	9,76E-01	4,21E-01	5,16E-01	Paired t-test	
CXCL9	O1D00771	Q07325	Chemotaxis; Promotes tumor immunity; Vascular and tissue remodeling	4,70E-11	3,01E-09	2,21E-06	2,03E-04	5,41E-06	1,42E-04	Paired t-test	
DCN	O1D00817	P07585	Vascular and tissue remodeling	1,08E-01	2,27E-01	8,83E-01	9,94E-01	5,26E-02	1,75E-01	Paired t-test	
EGF	O1D00759	P01133	Vascular and tissue remodeling	1,73E-01	3,07E-01	7,75E-01	9,76E-01	4,94E-02	1,75E-01	Paired t-test	
FASLG	O1D00792	P48023	Apoptosis/cell killing	1,26E-02	7,25E-02	1,07E-01	5,45E-01	5,29E-02	1,75E-01	Paired t-test	
GF2	O1D00770	P09038	Vascular and tissue remodeling	3,04E-02	9,91E-02	1,78E-01	6,18E-01	9,56E-02	2,25E-01	Paired t-test	
Gai-1	O1D00802	P09382	Promotes tumor immunity	6,91E-01	7,45E-01	7,27E-01	9,76E-01	4,72E-01	6,75E-01	Paired t-test	
Gai-9	O1D00779	Q00182	Apoptosis/cell killing; Suppresses tumor immunity; Vascular and tissue remodeling	9,81E-01	4,72E-01	8,44E-02	4,85E-01	9,01E-01	9,21E-01	Paired t-test	
GZMA	O1D00804	P12544	Apoptosis/cell killing	1,22E-02	7,25E-02	7,58E-03	1,16E-01	6,19E-02	1,75E-01	Paired t-test	
GZMB	O1D00840	P10144	Apoptosis/cell killing	2,74E-02	9,91E-02	8,41E-02	4,85E-01	1,21E-01	2,43E-01	Paired t-test	
GZMH	O1D00783	P20718	Apoptosis/cell killing	1,68E-01	3,03E-01	6,47E-01	9,76E-01	1,95E-01	3,28E-01	Paired t-test	
HGF	O1D00803	P14210	Vascular and tissue remodeling	2,99E-02	9,91E-02	3,51E-01	7,53E-01	4,35E-02	1,75E-01	Paired t-test	
HO-1	O1D00801	P09601	Metabolism	9,41E-01	9,91E-01	9,46E-01	9,94E-01	9,67E-01	9,67E-01	Paired t-test	
ICOSLg	O1D00828	Q75144	Promotes tumor immunity	3,14E-02	9,91E-02	7,51E-01	9,76E-01	1,18E-02	8,33E-02	Paired t-test	
IFN-gamma	O1D00552	P01579	Promotes tumor immunity	4,40E-01	5,25E-01	3,76E-01	7,53E-01	8,13E-01	8,40E-01	Paired t-test	
IL-1 alpha	O1D00757	P01583	Promotes tumor immunity; Suppresses tumor immunity; Vascular and tissue remodeling	2,92E-01	4,13E-01	4,08E-01	7,98E-01	4,53E-01	5,34E-01	Paired t-test	
IL10	O1D00809	P22301	Suppresses tumor immunity	9,52E-01	9,71E-01	3,75E-01	7,53E-01	6,84E-01	7,49E-01	Paired t-test	
IL12	O1D00842	P29459,P29460	Promotes tumor immunity	8,20E-02	1,95E-01	3,64E-01	7,53E-01	1,43E-01	2,79E-01	Paired t-test	
IL2RB1	O1D00835	Q42701	Promotes tumor immunity	4,48E-03	1,22E-01	1,23E-01	6,56E-01	1,13E-01	1,75E-01	Paired t-test	
IL3	O1D00836	P35225	Suppresses tumor immunity	4,61E-01	5,36E-01	9,93E-01	9,94E-01	3,64E-01	4,78E-01	Paired t-test	
IL5	O1D00551	P40933	Chemotaxis; Promotes tumor immunity; Suppresses tumor immunity	6,83E-01	7,48E-01	9,94E-01	9,94E-01	5,81E-01	6,43E-01	Paired t-test	
IL8	O1D00782	Q14116	Promotes tumor immunity; Suppresses tumor immunity	1,56E-01	3,03E-01	2,36E-01	6,58E-01	4,06E-01	5,12E-01	Paired t-test	
IL4	O1D00778	P60568	Promotes tumor immunity	3,66E-01	4,71E-01	9,78E-01	9,94E-01	2,71E-01	4,04E-01	Paired t-test	
IL33	O1D00780	Q05160	Suppresses tumor immunity	2,43E-01	3,66E-01	9,27E-01	9,94E-01	1,51E-01	2,80E-01	Paired t-test	
IL2	O1D00833	P05112	Suppresses tumor immunity	2,75E-01	4,02E-01	6,31E-01	9,76E-01	2,99E-01	4,47E-01	Paired t-test	
IL5	O1D00802	P05113	Suppresses tumor immunity	1,24E-01	2,47E-01	1,81E-01	6,18E-01	3,56E-01	4,78E-01	Paired t-test	
IL6	O1D00763	P05231	Promotes tumor immunity; Suppresses tumor immunity	3,52E-01	4,63E-01	7,95E-01	9,94E-01	3,62E-01	4,78E-01	Paired t-test	
IL7	O1D00761	P13232	Promotes tumor immunity	1,61E-01	3,03E-01	7,92E-01	9,76E-01	9,26E-02	2,24E-01	Paired t-test	
IL8	O1D00752	P10145	Chemotaxis; Suppresses tumor immunity; Vascular and tissue remodeling	4,31E-01	5,22E-01	7,94E-01	9,76E-01	4,59E-01	5,56E-01	Paired t-test	
KIR3DL1	O1D00550	P43629	Suppresses tumor immunity	3,10E-01	4,25E-01	9,78E-01	9,94E-01	1,67E-01	3,02E-01	Paired t-test	
KLRF1	O1D00839	Q13241	Promotes tumor immunity	3,18E-02	9,91E-02	3,75E-01	7,53E-01	4,64E-02	1,75E-01	Paired t-test	
LAG3	O1D00553	P18627	Suppresses tumor immunity	2,09E-01	3,44E-01	4,35E-01	8,18E-01	3,30E-01	4,68E-01	Paired t-test	
LAMP3	O1D00826	Q9UQV4	Suppresses tumor immunity	1,37E-02	7,40E-02	1,71E-01	6,18E-01	4,19E-02	1,75E-01	Paired t-test	
LAP TGF-beta-1	O1D00785	P01137	Suppresses tumor immunity	5,07E-01	5,81E-01	9,38E-01	9,94E-01	4,47E-01	5,34E-01	Paired t-test	
MCP-1	O1D00761	P13500	Chemotaxis; Vascular and tissue remodeling	2,34E-01	3,63E-01	7,53E-01	9,76E-01	2,13E-01	3,44E-01	Paired t-test	
MCP-2	O1D00795	P80075	Chemotaxis	1,67E-01	3,03E-01	6,66E-01	9,76E-01	1,80E-01	3,11E-01	Paired t-test	
MCP-3	O1D00755	P80098	Chemotaxis	5,74E-02	1,47E-01	7,33E-02	4,85E-01	2,10E-01	3,44E-01	Paired t-test	
MCP-4	O1D00768	Q99616	Chemotaxis; Suppresses tumor immunity; Vascular and tissue remodeling	3,13E-01	4,23E-01	3,52E-01	7,53E-01	5,06E-02	1,75E-01	Paired t-test	
MIC-A/B	O1D00820	Q29983,Q29980	Suppresses tumor immunity	5,31E-01	5,89E-01	9,46E-01	9,94E-01	4,13E-01	5,14E-01	Paired t-test	
MMP12	O1D00829	P39900	Suppresses tumor immunity; Vascular and tissue remodeling	1,93E-01	3,26E-01	5,53E-01	9,42E-01	2,35E-01	3,73E-01	Paired t-test	
MMP7	O1D00814	P09237	Apoptosis/cell killing; Suppresses tumor immunity	8,72E-02	1,96E-01	3,06E-01	7,53E-01	1,74E-01	3,08E-01	Paired t-test	
MUC-16	O1D00549	Q8WXI7	Suppresses tumor immunity	8,67E-04	1,14E-02	3,95E-03	9,08E-02	8,07E-02	2,12E-01	Paired t-test	
NCR1	O1D00816	Q76036	Promotes tumor immunity	5,14E-01	5,81E-01	9,89E-01	9,94E-01	3,76E-01	4,87E-01	Paired t-test	
NO53	O1D00777	P29474	Vascular and tissue remodeling	9,61E-01	9,71E-01	1,93E-01	6,34E-01	2,51E-01	3,85E-01	Paired t-test	
PD-L1	O1D00799	Q9N207	Suppresses tumor immunity	9,36E-03	6,69E-02	2,25E-01	6,56E-01	1,60E-02	1,00E-01	Paired t-test	
PD-L2	O1D00831	Q08021	Suppresses tumor immunity	1,20E-01	2,45E-01	7,63E-01	9,76E-01	2,77E-02	1,41E-01	Paired t-test	
PCD1	O1D00791	Q15116	Suppresses tumor immunity	1,80E-03	1,81E-02	9,65E-02	5,22E-01	8,26E-03	7,44E-02	Paired t-test	
PDGF subunit B	O1D00790	P01127	Vascular and tissue remodeling	1,93E-01	3,26E-01	4,79E-01	8,64E-01	2,50E-01	3,85E-01	Paired t-test	
PGF	O1D00762	P49763	Vascular and tissue remodeling	1,95E-01	3,26E-01	9,93E-01	9,94E-01	1,10E-01	2,35E-01	Paired t-test	
PTN	O1D00823	P21246	Vascular and tissue remodeling	3,84E-01	4,72E-01	2,92E-01	7,53E-01	7,00E-01	7,49E-01	Paired t-test	
THE2	O1D00754	Q02763	Vascular and tissue remodeling	2,14E-01	3,45E-01	6,09E-01	9,76E-01	6,11E-02	1,75E-01	Paired t-test	
TNF	O1D00554	P01375	Promotes tumor immunity; Suppresses tumor immunity; Vascular and tissue remodeling	2,57E-01	3,81E-01	7,49E-01	9,76E-01	2,72E-01	4,04E-01	Paired t-test	
TNFRSF12A	O1D00810	Q9N984	Apoptosis/cell killing; Vascular and tissue remodeling	1,97E-02	9,52E-02	1,45E-01	5,87E-01	7,36E-02	1,99E-01	Paired t-test	
TNFRSF21	O1D00818	Q75509	Apoptosis/cell killing	4,88E-02	1,28E-01	2,45E-02	3,22E-01	4,84E-01	5,43E-01	Paired t-test	
TNFRSF4	O1D00819	P43489	Promotes tumor immunity	3,23E-02	9,91E-02	3,44E-01	7,53E-01	4,02E-02	1,75E-01	Paired t-test	
TNFRSF9	O1D00752	Q07011	Promotes tumor immunity	2,93E-02	9,91E-02	1,44E-01	5,87E-01	1,14E-01	2,38E-01	Paired t-test	
TNFSF14	O1D00787	Q43557	Promotes tumor immunity	3,71E-01	4,71E-01	9,05E-01	9,94E-01	3,05E-01	4,38E-01	Paired t-test	
TRAIL	O1D00769	P05091	Apoptosis/cell killing	1,40E-03	1,62E-02	7,38E-02	4,85E-01	8,90E-03	7,44E-02	Paired t-test	
TWEAK	O1D00789	Q43508	Apoptosis/cell killing; Vascular and tissue remodeling	3,10E-01	4,23E-01	1,49E-01	5,87E-01	6,95E-01	7,49E-01	Paired t-test	
VEGFA	O1D00832	P15692	Vascular and tissue remodeling	9,01E-02	1,97E-						

**Supplementary Table S2:** Gene lists used for the RNA-based estimation of immune cell populations. Gene lists were obtained from<sup>14</sup>, except gene markers for CD4 T-cells, which were obtained from<sup>13</sup>.

<b>Immune cell population</b>	<b>Gene list</b>
B cells	<i>MS4A1, SPIB</i>
CD4+ T cells	<i>AMIGO2, CD40LG, ICOS, IGFBP4, ITM2A, TRAT1</i>
CD45	<i>PTPRC</i>
CD8+ T cells	<i>CD8A, CD8B</i>
Cytotoxic cells	<i>CTSW, GNLY, GZMA, GZMB, GZMH, KLRB1, KLRD1, KLRK1, NKG7, PRF1</i>
Dendritic cells	<i>CCL13, CD209, HSD11B1</i>
Exhausted CD8+ T cells	<i>CD244, EOMES, LAG3, PTGER4</i>
Macrophages	<i>CD163, CD68, CD84, MS4A4A</i>
Mast cells	<i>CPA3, HDC, MS4A2, TPSAB1, TPSB2</i>
Neutrophils	<i>CSF3R, FCGR3B, FPR1, SIGLEC5</i>
NK CD56- cells	<i>IL21R</i>
NK cells	<i>XCL1</i>
T cells	<i>CD3D, CD3E, CD3G, CD6, SH2D1A, TRAT1</i>
T <sub>H</sub> 1 cells	<i>TBX21</i>
Tregs	<i>FOXP3</i>

## Supplementary Materials and Methods

### Clinical samples

Tumor biopsies were either dry-frozen or fresh frozen (FF) embedded in TissueTek OCTTM Compound (Sakura Finetek), snap-frozen in liquid nitrogen and stored at -80°C or obtained from formalin fixed paraffin embedded (FFPE) samples. Blood samples from all patients were stored in EDTA tubes at -80°C. Urine supernatants were centrifuged and stored at -80°C. Urine samples for protein analyses were sampled at a maximum of four months before and after BCG treatment.

### DNA and RNA extraction

Tumor DNA from FF and dry-frozen tumors was extracted with Genra Puregene Tissue Kit (Qiagen). DNA from FFPE samples was extracted using AllPrep DNA/RNA Kit (Qiagen). From peripheral blood, leukocyte DNA for germline (GL) reference was extracted using Qiasymphony DSP DNA midi kit (Qiagen) for all patients. Total Tumor RNA was extracted using RNeasy Mini and Micro Kits (Qiagen).

From tumors, haematoxylin and eosin (HE) stained sections of 4 µm were included to estimate carcinoma cell percentage.

DNA and RNA from tumors were extracted from serial cryosections of 20-25 µm. DNA from FFPE tumor specimens was extracted using punches taken from areas of the tumor with high estimated carcinoma cell percentage.

Urine (20–50 ml) was centrifuged at 3000G for 10 minutes, and supernatants were stored at -80°C. Urine samples were thawed on ice, 10µl of urine was stored for Olink proteomics analyses (described below), PBS was added to remaining urine for a total volume of 4ml, and samples were centrifuged at 3000G for 10 minutes. Total cell-free DNA (cfDNA) was extracted from a median of 3.6 ml urine supernatants (range 0.7–3.65 ml). 10% ATL lysis buffer (median: 400µl, range: 100µl-500µl) (Qiagen, Aarhus, Denmark) was added, samples were incubated for 1.5-2h at room temperature followed by centrifugation at 1300G for 10 minutes. cfDNA extraction was performed using the QIASymphony DSP Circulating DNA Kit (Qiagen). DNA was eluted in 60 µl ddH<sub>2</sub>O in DNA lobind tubes (Sigma-Aldrich).

## Design of custom panel for targeted sequencing

For deep targeted sequencing of tumor specific mutations, we designed NGS panels where unique mutations (n=10-71) from 154 patients were included. Single nucleotide variants (SNVs) for the panels were selected from tumor guided WES analysis. Three panels covering mutations from 48, 54, and 52 patients, respectively, were designed.

SNVs were included based on the following criteria: 1. High or moderate impact mutations were favored. 2) Mutations with high variant allele frequencies (VAFs). 3) Mutations in known oncogenic genes from OncoKB. 4) Bladder cancer associated genes (The Cancer Genome Atlas<sup>1,2</sup>, MSKCC cBioPortal for Cancer Genomics<sup>3,4</sup>, Uromol 2021<sup>3,4</sup>, and Lamy *et al*<sup>5</sup>). 5) Mutations in the most exonically variable genes, reported by the Ingenuity Variant Analysis (IVA) software and/or at error-prone positions/in commonly reported erroneous contexts (C>T) were excluded, unless present in cancer driver genes or known bladder cancer genes. The three panels differed slightly in mutation selection.

## Library preparation, deep-targeted sequencing and Mutation Calling of urinary

NGS libraries of cfDNA from urine supernatant were prepared using a modified version of the Mechanical Fragmentation Library preparation kit from Twist Bioscience in order to increase small fragment preservation and increase conversion rate. For robust error correction, 9 bp Unique Molecular Identifiers (UMI) were incorporated by replacing the twist adaptors with xGen™ UDI-UMI Adapters (Integrated DNA Technologies). The maximum cfDNA input was set to 100ng with no lower limit. Target enrichment was conducted using a modified version of the Twist Target Enrichment Protocol (Twist Bioscience) in combination with custom Twist panels (each SNV was captured by 120 bp probes on both strands). UMI consensus base calls were called using the fgbio tool package (v1.4.0). The ClipBAM (Hard-clipping) function of fgbio was enabled to avoid double count of variant calls of reads from the same template by clipping overlap between the reads. This was used for calculating UMI family size and UMI read depth. For UMI consensus collapsing, three reads were required as minimum and an editing distance of one was allowed. However, for secondary alignments, reads were not clipped. Realignment at INDEL positions were made using abra2 (v2.24). DeepSNV<sup>6</sup> was applied for detection and quantification of low-frequency tdDNA mutations in urine samples.

Calculations of UMI consensus read depth and UMI family sizes were based on the fgbio tool package (v1.4.0) that was run with the ClipBAM (Hard-clipping) function. Realignment at

INDEL positions are made using abra2 (v2.24). For UMI consensus collapsing, three reads were required as minimum and an editing distance of one was allowed.

Reads were mapped against the hg38 genome using bwa mem v.0.7.17. Mapped reads were grouped and consensus reads were generated from UMIs. Hereafter, read counts for the positions included in the panel were evaluated using the pileup tool bam read count. Only mutations detected in both the 5'-3' direction and the 3'-5' direction were included. Furthermore, at least three reads with different UMIs supporting a given mutation were required.

Copies per ml were calculated as follows:

$$\text{GE/ml} = (\text{DNA input}(\text{ng}) * \text{VAF} * (1000 \text{ pg/ng}) / (3.3 \text{ pg/GE})) / \text{urine (ml)}$$

Clearance of tumor derived DNA (tdDNA) was defined as VAF  $\neq$  0 in pre-BCG samples and VAF=0 in post-BCG samples.

## Neoantigen Calling

HLA types were called using POLYSOLVER<sup>7</sup>, xHLA<sup>8</sup>, and OptiType<sup>9</sup>, with patient HLA type decided by consensus vote supported by at least two algorithms. If no majority could be reached, POLYSOLVER was used. All novel 9-11mer peptide fragments were generated by MuPeXI<sup>10</sup> and eluted ligands (EL) rank-percentage scores for all HLA alleles were predicted by NetMHCpan-4.1<sup>11</sup>. The rank-percentage score represents the rank of the fragments EL probability compared to a set of random natural peptides. A mutation was considered a neoantigen if at least one fragment had an EL rank percentage score < 2%, for at least one HLA allele.

## DeepSNV

The inclusion of genomic positions associated with multiple patients on every custom panel, facilitates an abundance of sequencing data for every genomic position with no mutations expected to be present. We exploited this by employing an analysis framework based on a maximum likelihood implementation of the shearwater algorithm developed by Gerstung *et al.*<sup>6</sup>. In brief, a background error model was built by fitting presumably non-mutated data, i.e. data from all samples not associated with a given mutation, to a binomial distribution with site-specific calculation of the dispersion for every mutation of interest. Samples with a VAF at a given position above 25% were excluded when generating the error model. Similarly, samples with a read depth below 50 at a given position were excluded when generating the error model. Furthermore, positions with an average error-rate above 10% across presumably non-mutated samples were excluded. Presumably mutated data, i.e. data from

the target positions of a given sample, was assessed for a statistical significant difference compared to the background error model. Resulting  $p$ -values were corrected for multiple testing using the Benjamini-Hochberg procedure and adjusted  $p$ -values below 0.05 were considered significant.

In addition, to exploit that data were generated for all positions in a custom panel for every sample, we established an analysis to assess the combined signal from all target positions for a given sample. We used Fisher's method to calculate the sum of logs for all  $p$ -values obtained when analyzing the target positions. To gauge a randomly expected level of signal, we randomly sampled the same number of mutations as the target positions from non-target positions and similarly calculated the sum of logs. This was performed 10,000 times. Only samples with a sum of log scores greater than all scores from random sampling were considered ctDNA positive.

## RNA sequencing data

Salmon<sup>12</sup> was used to quantify the expression of transcripts using annotation from the Gencode release 33 on genome assembly GRCh38.

Spiderplots were generated using the Radarchart function in the R package fmsb.

We estimated immune cell populations from the RNA-seq data using established gene expression signatures as in Rosenthal *et al.*<sup>13–15</sup>. A score for each immune cell population was calculated as the mean expression of all marker genes for the given cell type and a total immune score was defined as the mean of all immune cell population scores. Individual scores for B-cells, neutrophils and NK-cells were not evaluated as genes were missing for these cell population signatures. Gene lists are available in Supplementary Table S3.

## WES analyses

MutationalPatterns was used for *de novo* extraction of mutational signatures<sup>16,17</sup>

## References

1. Robertson, A. G. *et al.* Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. *Cell* **174**, 1033 (2018).
2. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of



- urothelial bladder carcinoma. *Nature* **507**, 315–322 (2014).
3. cBioPortal for Cancer Genomics. <https://www.cbioportal.org/>.
  4. Linskrog, S. V. *et al.* An integrated multi-omics analysis identifies clinically relevant molecular subtypes of non-muscle-invasive bladder cancer. *Urology* (2020) doi:10.1101/2020.06.19.20054809.
  5. Lamy, P. *et al.* Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma. *Cancer Res.* **76**, 5894–5906 (2016).
  6. Gerstung, M. *et al.* Reliable detection of subclonal single-nucleotide variants in tumour cell populations. *Nat. Commun.* **3**, 811 (2012).
  7. Shukla, S. A. *et al.* Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. *Nat. Biotechnol.* **33**, 1152–1158 (2015).
  8. Xie, C. *et al.* Fast and accurate HLA typing from short-read next-generation sequence data with xHLA. *Proc. Natl. Acad. Sci. U. S. A.* **114**, 8059–8064 (2017).
  9. Szolek, A. *et al.* OptiType: precision HLA typing from next-generation sequencing data. *Bioinformatics* **30**, 3310–3316 (2014).
  10. Bjerregaard, A.-M., Nielsen, M., Hadrup, S. R., Szallasi, Z. & Eklund, A. C. MuPeXI: prediction of neo-epitopes from tumor sequencing data. *Cancer Immunol. Immunother.* **66**, 1123–1130 (2017).
  11. Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. *Nucleic Acids Res.* **48**, W449–W454 (2020).
  12. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. *Nat. Methods* **14**, 417–419 (2017).
  13. Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. *Science* **355**, (2017).

14. DanaHER, P. *et al.* Gene expression markers of Tumor Infiltrating Leukocytes. *J Immunother Cancer* **5**, 18 (2017).
15. Rosenthal, R. *et al.* Neoantigen-directed immune escape in lung cancer evolution. *Nature* **567**, 479–485 (2019).
16. Manders, F. *et al.* MutationalPatterns: the one stop shop for the analysis of mutational processes. *BMC Genomics* **23**, 134 (2022).
17. Blokzijl, F., Janssen, R., van Boxtel, R. & Cuppen, E. MutationalPatterns: comprehensive genome-wide analysis of mutational processes. *Genome Med.* **10**, 33 (2018).